Antibody discovery
Document text
Principal Investigator: Anton Simeonov Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES Fiscal Year: 2023 Award: $125,849 Funding agency: National Center for Advancing Translational Sciences The antibody discovery project harnesses the therapeutic potential of small biologicals known as nanobodies. By constructing a humanized llama phage display library for use here at NCATS, it is possible to screen for therapeutically relevant nanobodies as needed. The small size of nanobodies makes them ideal for binding inside protein folds and clefts that are generally inaccessible to conventional antibodies. This allows NCATS to pursue avenues of therapeutic development that have not yet been explored. Recent work includes identifying binders against the SARS-CoV-2 RBD to decrease viral cell entry. Through NIH collaborations, the binding of these nanobodies to the SARS-CoV-2 spike trimer domains were imaged by CryoEM. A screen for modulators of CD206 to trigger reprogramming in tumor-associated macrophages is also underway. Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Antibodies><Binding><COVID-19 virus><COVID19 virus><Cell Body><Cells><CoV-2><CoV2><Collaborations><Cryo-electron Microscopy><Cryoelectron Microscopy><Electron Cryomicroscopy><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G-Protein-Coupled Receptors><GPCR><Goals><Image><Libraries><Llama><Methods><Molecular Interaction><NCATS><NIH><National Center for Advancing Translational Sciences><National Institutes of Health><Patients><Phage Display><Production><Proteins><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Therapeutic><Tumor-associated macrophages><United States National Institutes of Health><Viral><Work><Wuhan coronavirus><coronavirus disease 2019 virus><coronavirus disease-19 virus><cryo-EM><cryoEM><cryogenic electron microscopy><hCoV19><imaging><nCoV2><nano sized><nanobodies><nanobody><nanosized><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><programs><protein folding><screening><screenings><sdAb><single domain antibodies><therapeutic agent development><therapeutic development>